The Role of a Cerebello-Thalamo-Basal Ganglia Pathway in Dystonia
小脑-丘脑-基底神经节通路在肌张力障碍中的作用
基本信息
- 批准号:8496145
- 负责人:
- 金额:$ 2.02万
- 依托单位:
- 依托单位国家:美国
- 项目类别:
- 财政年份:2010
- 资助国家:美国
- 起止时间:2010-07-01 至 2014-06-30
- 项目状态:已结题
- 来源:
- 关键词:AdoptedAgonistAnimalsAreaBasal GangliaBehaviorBehavior assessmentBrainCell NucleusCerebellar DiseasesCerebellumCharacteristicsCommunicationDataDeep Brain StimulationDiseaseDystoniaDystonia 12EtiologyFinancial compensationFunctional disorderGenerationsGeneticGoalsHumanInterventionIntralaminar Nuclear GroupLesionLinkMediatingMethodsModelingMotorMovement DisordersMusMuscleMuscle ContractionNa(+)-K(+)-Exchanging ATPaseNatureNeurologicNeuromodulatorNeuronsOuabainOutputPainPathway interactionsPatientsPatternPerfusionPharmaceutical PreparationsPhysiologicalPlayPosturePreventionPrimatesPurkinje CellsRattusResearchRodentRodent ModelRoleSecondary DystoniaSignal TransductionSiteStructureSymptomsTestingThalamic NucleiThalamic structureTravelWorkawakecerebellar lesionextracellularin vivoinsightpreventpublic health relevanceresearch studyresponse
项目摘要
DESCRIPTION (provided by applicant): Dystonia is a movement disorder characterized by simultaneous and prolonged co-contraction of agonist and antagonist muscles, causing patients to adopt painful twisting postures. The dystonias are heterogeneous in their etiologies and few of these are well understood. Dystonia can be generated by lesions in the basal ganglia and many genetic and secondary dystonias are associated with altered basal ganglia activity suggesting the basal ganglia plays a role in this disorder. Certain dystonias present after cerebellar insult and others are relieved by lesion of the cerebellar output nuclei suggesting that the cerebellum may be involved in certain cases of dystonia. In rodents, perfusing a selective Na/K ATPase (sodium pump) blocker ouabain into the cerebellum results in dystonia. Studies in our lab suggest this mechanism of dystonia generation may be important in a particular genetic dystonia, DYT12 or Rapid-Onset Dystonia- Parkinsonism. We suggest that in this model, aberrant activity in the cerebellum is transferred to the basal ganglia and mediates the observed dystonia. A disynaptic connection between the cerebellar output nuclei and basal ganglia input nuclei has been identified in rodents and primates. The physiologic role of this pathway is currently unknown. In this proposal we evaluate the role of this disynaptic pathway and specifically one of its intermediate nuclei, the centrolateral nucleus of the thalamus (CL), in dystonia induced by ouabain administration to the cerebellum. Preliminary studies suggest that lesioning of CL prior to ouabain perfusion prevents the generation of dystonia. In this proposal we will test if this prevention is long term and if it is accompanied by other motor abnormalities. We will also explore CL as a potential site of intervention after animals already have dystonia. Finally we will determine how CL neuron firing changes in response to ouabain perfusion onto the cerebellum. This should give us insight into the role of the disynaptic pathway through CL in diseased animals and help up develop new interventions to test on dystonic ouabain perfused mice including pharmacologic treatments and deep brain stimulation. These experiments together will help define one mechanism of dystonia induction and suggest new methods to alleviate dystonia in certain human cases.
描述(由申请人提供):肌张力障碍是一种运动障碍,其特征为激动肌和拮抗肌同时和长期共同收缩,导致患者采取痛苦的扭转姿势。肌张力障碍的病因是异质性的,其中很少有很好的理解。肌张力障碍可由基底神经节病变产生,许多遗传性和继发性肌张力障碍与基底神经节活动改变相关,表明基底神经节在这种疾病中起作用。某些肌张力障碍出现在小脑损伤后,而另一些则因小脑输出核团的损伤而缓解,这表明小脑可能参与了某些肌张力障碍病例。在啮齿类动物中,将选择性Na/K ATP酶(钠泵)阻断剂哇巴因灌注到小脑中会导致肌张力障碍。我们实验室的研究表明,这种肌张力障碍产生的机制可能在特定的遗传性肌张力障碍,DYT 12或快速发作的肌张力障碍-帕金森综合征中很重要。我们认为,在这个模型中,小脑的异常活动转移到基底神经节,并介导观察到的肌张力障碍。在啮齿动物和灵长类动物中,小脑输出核团和基底神经节输入核团之间存在双突触联系。该途径的生理作用目前尚不清楚。在这个建议中,我们评估的作用,这种双突触通路,特别是它的中间核,丘脑(CL)的中央外侧核,哇巴因管理引起的肌张力障碍的小脑。初步研究表明,哇巴因灌注前CL损伤可防止肌张力障碍的产生。在本建议中,我们将测试这种预防是否是长期的,以及是否伴有其他运动异常。我们还将探索CL作为动物已经患有肌张力障碍后的潜在干预部位。最后,我们将确定如何CL神经元放电的变化,以响应哇巴因灌注到小脑。这应该让我们深入了解通过CL在患病动物中的双突触通路的作用,并帮助开发新的干预措施,以测试对张力障碍的哇巴因灌注小鼠,包括药物治疗和脑深部刺激。这些实验将有助于确定肌张力障碍诱导的一种机制,并提出新的方法来缓解某些人类病例中的肌张力障碍。
项目成果
期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)
数据更新时间:{{ journalArticles.updateTime }}
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
数据更新时间:{{ journalArticles.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ monograph.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ sciAawards.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ conferencePapers.updateTime }}
{{ item.title }}
- 作者:
{{ item.author }}
数据更新时间:{{ patent.updateTime }}
Rachel Fremont其他文献
Rachel Fremont的其他文献
{{
item.title }}
{{ item.translation_title }}
- DOI:
{{ item.doi }} - 发表时间:
{{ item.publish_year }} - 期刊:
- 影响因子:{{ item.factor }}
- 作者:
{{ item.authors }} - 通讯作者:
{{ item.author }}
{{ truncateString('Rachel Fremont', 18)}}的其他基金
The Role of a Cerebello-Thalamo-Basal Ganglia Pathway in Dystonia
小脑-丘脑-基底神经节通路在肌张力障碍中的作用
- 批准号:
8003752 - 财政年份:2010
- 资助金额:
$ 2.02万 - 项目类别:
The Role of a Cerebello-Thalamo-Basal Ganglia Pathway in Dystonia
小脑-丘脑-基底神经节通路在肌张力障碍中的作用
- 批准号:
8209453 - 财政年份:2010
- 资助金额:
$ 2.02万 - 项目类别:
The Role of a Cerebello-Thalamo-Basal Ganglia Pathway in Dystonia
小脑-丘脑-基底神经节通路在肌张力障碍中的作用
- 批准号:
8300123 - 财政年份:2010
- 资助金额:
$ 2.02万 - 项目类别:
相似国自然基金
Agonist-GPR119-Gs复合物的结构生物学研究
- 批准号:32000851
- 批准年份:2020
- 资助金额:24.0 万元
- 项目类别:青年科学基金项目
相似海外基金
S1PR1 agonistによる脳血液関門制御を介した脳梗塞の新規治療法開発
S1PR1激动剂调节血脑屏障治疗脑梗塞新方法的开发
- 批准号:
24K12256 - 财政年份:2024
- 资助金额:
$ 2.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)
AHR agonistによるSLE皮疹の新たな治療薬の開発
使用 AHR 激动剂开发治疗 SLE 皮疹的新疗法
- 批准号:
24K19176 - 财政年份:2024
- 资助金额:
$ 2.02万 - 项目类别:
Grant-in-Aid for Early-Career Scientists
Evaluation of a specific LXR/PPAR agonist for treatment of Alzheimer's disease
特定 LXR/PPAR 激动剂治疗阿尔茨海默病的评估
- 批准号:
10578068 - 财政年份:2023
- 资助金额:
$ 2.02万 - 项目类别:
AUGMENTING THE QUALITY AND DURATION OF THE IMMUNE RESPONSE WITH A NOVEL TLR2 AGONIST-ALUMINUM COMBINATION ADJUVANT
使用新型 TLR2 激动剂-铝组合佐剂增强免疫反应的质量和持续时间
- 批准号:
10933287 - 财政年份:2023
- 资助金额:
$ 2.02万 - 项目类别:
Targeting breast cancer microenvironment with small molecule agonist of relaxin receptor
用松弛素受体小分子激动剂靶向乳腺癌微环境
- 批准号:
10650593 - 财政年份:2023
- 资助金额:
$ 2.02万 - 项目类别:
AMPKa agonist in attenuating CPT1A inhibition and alcoholic chronic pancreatitis
AMPKa 激动剂减轻 CPT1A 抑制和酒精性慢性胰腺炎
- 批准号:
10649275 - 财政年份:2023
- 资助金额:
$ 2.02万 - 项目类别:
A randomized double-blind placebo controlled Phase 1 SAD study in male and female healthy volunteers to assess safety, pharmacokinetics, and transient biomarker changes by the ABCA1 agonist CS6253
在男性和女性健康志愿者中进行的一项随机双盲安慰剂对照 1 期 SAD 研究,旨在评估 ABCA1 激动剂 CS6253 的安全性、药代动力学和短暂生物标志物变化
- 批准号:
10734158 - 财政年份:2023
- 资助金额:
$ 2.02万 - 项目类别:
Investigating mechanisms underpinning outcomes in people on opioid agonist treatment for OUD: Disentangling sleep and circadian rhythm influences on craving and emotion regulation
研究阿片类激动剂治疗 OUD 患者结果的机制:解开睡眠和昼夜节律对渴望和情绪调节的影响
- 批准号:
10784209 - 财政年份:2023
- 资助金额:
$ 2.02万 - 项目类别:
A novel nanobody-based agonist-redirected checkpoint (ARC) molecule, aPD1-Fc-OX40L, for cancer immunotherapy
一种基于纳米抗体的新型激动剂重定向检查点 (ARC) 分子 aPD1-Fc-OX40L,用于癌症免疫治疗
- 批准号:
10580259 - 财政年份:2023
- 资助金额:
$ 2.02万 - 项目类别:
Identification and characterization of a plant growth promoter from wild plants: is this a novel plant hormone agonist?
野生植物中植物生长促进剂的鉴定和表征:这是一种新型植物激素激动剂吗?
- 批准号:
23K05057 - 财政年份:2023
- 资助金额:
$ 2.02万 - 项目类别:
Grant-in-Aid for Scientific Research (C)














{{item.name}}会员




